These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 4280523)

  • 1. Suppression by the spironolactone metabolite canrenone of plasma testosterone in man.
    Erbler HC
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 285(4):403-6. PubMed ID: 4280523
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of aldosterone production in diuretic-induced hyperaldosteronism by aldosterone antagonist canrenone in man.
    Erbler HC
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 285(4):395-401. PubMed ID: 4280522
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of spironolactone and canrenone on the digoxin radioimmunoassay.
    Huffman DH
    Res Commun Chem Pathol Pharmacol; 1974 Dec; 9(4):787-90. PubMed ID: 4477402
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
    Sadée W; Dagcioglu M; Schröder R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of aldosterone antagonists on organ cultures of human prostatic tissue.
    Castro JE; Sellwood RA
    J Pathol; 1974 Aug; 113(4):217-22. PubMed ID: 4139252
    [No Abstract]   [Full Text] [Related]  

  • 6. Enhancement by food of canrenone bioavailability from spironolactone.
    Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
    Krause W; Karras J; Jakobs U
    J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is canrenone the major metabolite of spironolactone?
    Merkus FW
    Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
    [No Abstract]   [Full Text] [Related]  

  • 10. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids.
    Neurath GB; Ambrosius D
    J Chromatogr; 1979 Jun; 163(2):230-5. PubMed ID: 541378
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparison of some extra-renal effects of spironolactone and canrenone.
    Huston GJ; Al-Dujaili EA
    Br J Clin Pharmacol; 1979 Apr; 7(4):385-92. PubMed ID: 444357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proceedings: Acute and chronic effects of the aldosterone antagonist spironolactone and its main metabolite canrenone on plasma aldosterone concentration, plasma renin activity, serum electrolytes and on the excretion of aldosterone, fluid and electrolytes in rats.
    Erbler HC; Hilfenhaus M
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R52. PubMed ID: 1143449
    [No Abstract]   [Full Text] [Related]  

  • 14. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
    Foukaridis GN
    Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of endocrine systemic side effects after topical application of spironolactone in man.
    Rey FO; Valterio C; Locatelli L; Ramelet AA; Felber JP
    J Endocrinol Invest; 1988 Apr; 11(4):273-8. PubMed ID: 3411088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.
    Cheng SC; Suzuki K; Sadee W; Harding BW
    Endocrinology; 1976 Oct; 99(4):1097-106. PubMed ID: 976190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone response related to plasma canrenone concentration [proceedings].
    Hettiarachchi J; Ramsay LE
    Br J Clin Pharmacol; 1979 Apr; 7(4):426P-427P. PubMed ID: 444376
    [No Abstract]   [Full Text] [Related]  

  • 20. [Aspects of the physiologic bioavailability of spironolactone and canrenone].
    Portal A; Gaillot J; Bieder A; Rodary C; Bertharion JJ
    Sem Hop Ther; 1976 Nov; 52(9):465-70. PubMed ID: 1006321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.